Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 410

1.

Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.

Di Giambenedetto S, Bracciale L, Colafigli M, Cattani P, Pinnetti C, Bacarelli A, Prosperi M, Fadda G, Cauda R, De Luca A.

Antivir Ther. 2007;12(5):835-9. Erratum in: Antivir Ther. 2007;12(7):1145. Colatigli, Manuela [corrected to Colafigli, Manuela; Cattani, Paola [added]; Pannetti, Carmen [corrected to Pinnetti, Carmen].

PMID:
17713168
2.

Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.

Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A; Antiretroviral Resistance Cohort Analysis Study Group..

Antivir Ther. 2009;14(3):359-69.

PMID:
19474470
3.

Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.

Novak RM, Chen L, MacArthur RD, Baxter JD, Huppler Hullsiek K, Peng G, Xiang Y, Henely C, Schmetter B, Uy J, van den Berg-Wolf M, Kozal M; Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team..

Clin Infect Dis. 2005 Feb 1;40(3):468-74. Epub 2005 Jan 10.

PMID:
15668873
4.

Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.

Lohse N, Jørgensen LB, Kronborg G, Møller A, Kvinesdal B, Sørensen HT, Obel N, Gerstoft J; Danish HIV Cohort Study..

Antivir Ther. 2007;12(6):909-17.

PMID:
17926645
5.

[Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].

Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D, Beerenwinkel N, Sagir A, Pfister H, Häussinger D.

Dtsch Med Wochenschr. 2007 May 4;132(18):977-82. German.

PMID:
17457780
6.

Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.

Cavalcanti AM, Lacerda HR, Brito AM, Pereira S, Medeiros D, Oliveira S.

Mem Inst Oswaldo Cruz. 2007 Nov;102(7):785-92. Epub 2007 Dec 11.

7.

Prevalence of antiretroviral drug resistance among treatment-naive and treated HIV-infected patients in Venezuela.

Rangel HR, Garzaro DJ, Torres JR, Castro J, Suarez JA, Naranjo L, Ossenkopp J, Martinez N; Resistance Committee Group., Gutierrez C, Pujol FH.

Mem Inst Oswaldo Cruz. 2009 May;104(3):522-5.

8.

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.

Zaccarelli M, Lorenzini P, Tozzi V, Forbici F, Ceccherini-Silberstein F, Gori C, D'Arrigo R, Trotta MP, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of the HIV Genotype Resistance Test (GRT) at the National Institute for Infectious Diseases "Lazzaro Spallanzani"..

Infection. 2009 Jun;37(3):203-9. doi: 10.1007/s15010-008-8142-8. Epub 2009 Mar 9.

PMID:
19274429
9.

Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.

Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test..

Antivir Ther. 2006;11(5):553-60.

PMID:
16964822
10.

The V118I mutation as a marker of advanced HIV infection and disease progression.

Zaccarelli M, Tozzi V, Lorenzini P, Forbici F, Narciso P, Ceccherini-Silberstein F, Trotta MP, Bertoli A, Liuzzi G, Marconi P, Mosti S, Perno CF, Antinori A.

Antivir Ther. 2007;12(2):163-8.

PMID:
17503658
11.

Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.

Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, Andreoni M.

J Med Virol. 2003 Jan;69(1):1-6.

PMID:
12436471
12.

HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.

Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML; French PRIMO Cohort Study Group (ANRS CO 06)..

AIDS. 2006 Jan 9;20(2):159-70.

PMID:
16511408
13.

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.

Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group..

AIDS. 2007 Mar 30;21(6):721-32.

PMID:
17413693
14.

Application of HIV-1 genotypic-resistance testing prevents the evolution of further resistance mutations in heavily pretreated patients.

Zöllner B, Feucht HH, Weitner L, Adam A, Schröter M, Schäfer P, Laufs R.

J Clin Virol. 2001 Apr;21(1):37-45.

PMID:
11255096
15.

Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.

Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr.

AIDS. 2007 Apr 23;21(7):825-34.

PMID:
17415037
16.

Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar years: a cohort study.

Bracciale L, Fanti I, Di Giambenedetto S, Colafigli M, Prosperi M, Bacarelli A, Santangelo R, Cattani P, Cauda R, De Luca A.

J Clin Virol. 2009 Nov;46(3):290-4. doi: 10.1016/j.jcv.2009.07.013. Epub 2009 Aug 21.

PMID:
19699675
17.

Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.

J Clin Virol. 2008 Apr;41(4):310-3. doi: 10.1016/j.jcv.2007.12.015. Epub 2008 Mar 7.

PMID:
18316243
18.

A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.

Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM.

Antivir Ther. 2002 Jun;7(2):123-9.

PMID:
12212924
19.

Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.

Murillo W, de Rivera IL, Parham L, Jovel E, Palou E, Karlsson AC, Albert J.

HIV Med. 2010 Feb;11(2):95-103. doi: 10.1111/j.1468-1293.2009.00747.x. Epub 2009 Aug 3.

20.

Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression.

Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein TL, Lundgren JD.

Scand J Infect Dis. 2005;37(11-12):890-901.

PMID:
16308226

Supplemental Content

Support Center